During the last session, Acasti Pharma Inc. (NASDAQ:ACST)’s traded shares were 9,862,254, with the beta value of the company hitting 0. At the end of the trading day, the stock’s price was $0.53, reflecting an intraday loss of -7.72% or -$0.04. The 52-week high for the ACST share is $1.22, that puts it down -130.19% from that peak though still a striking +67.92% gain since the share price plummeted to a 52-week low of $0.17. The company’s market capitalization is $107.67 Million, and the average intraday trading volume over the past 10 days was 6.94 Million shares, and the average trade volume was 38.42 Million shares over the past three months.
Acasti Pharma Inc. (ACST) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 2. ACST has a Sell rating from none of the analyst(s) out of 1 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and no one recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.16.
Acasti Pharma Inc. (NASDAQ:ACST): Trading Information
Acasti Pharma Inc. (ACST) registered a -7.72% downside in the last session and has traded in the red over the past 5 sessions. The stock spiked 17.81% in intraday trading to $0.64 this Thursday, Apr 01, hitting a weekly high. The stock’s 5-day price performance is -10.85%, and it has moved by -16.56% in 30 days. Despite these dips, the overall price performance for the year is 61.85%. The short interest in Acasti Pharma Inc. (NASDAQ:ACST) is 3.58 Million shares and it means that shorts have 0.09 day(s) to cover.
The consensus price target of analysts on Wall Street is $0.25, which implies a decline of -52.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $0.25 and $0.25 respectively. As a result, ACST is trading at a discount of -52.83% off the target high and -52.83% off the low.
Acasti Pharma Inc. (ACST) projections and forecasts
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated 0%. While earnings are projected to return 30.3% in 2021, the next five years will return 0% per annum.
Acasti Pharma Inc. (NASDAQ:ACST)’s Biggest Investors
Acasti Pharma Inc. insiders own 2.7% of total outstanding shares while institutional holders control 2.22%, with the float percentage being 2.28%. Renaissance Technologies, LLC is the largest shareholder of the company, while 31 institutions own stock in it. As of Dec 30, 2020, the company held over 1.92 Million shares (or 0.96% of all shares), a total value of $625.3 Thousand in shares.
The next largest institutional holding, with 687.99 Thousand shares, is of Virtu Financial LLC’s that is approximately 0.34% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $223.6 Thousand.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.